Flovent (Fluticasone) with Honey for Eosinophilic Esophagitis (EOE)
Topical fluticasone (Flovent) can be effectively administered with honey as a vehicle for the treatment of eosinophilic esophagitis, as this delivery method may improve medication adherence and esophageal contact time compared to standard inhaler administration. 1
Treatment Options for EOE
First-Line Treatments
- Topical steroids are highly effective for inducing histological and clinical remission in EOE with strong evidence supporting their use 1
- Proton pump inhibitors (PPIs) are also effective first-line therapy, given twice daily for 8-12 weeks before assessing response 1
- Dietary approaches, including elimination diets, can be effective but have compliance challenges 1
Topical Steroid Administration Methods
Standard Administration
- Traditional method involves swallowing puffs from a metered dose inhaler (MDI) without inhaling 1
- For fluticasone (Flovent), typical dosing:
- After administration, patients should not eat, drink, or rinse for 30 minutes 1
Viscous Preparations
- Mixing topical steroids with viscous carriers (like honey) can improve:
Evidence for Fluticasone in EOE
- Swallowed fluticasone has been shown to induce histologic remission in 50% of patients compared to 9% with placebo 2
- Long-term maintenance therapy with swallowed fluticasone demonstrates sustained reduction in esophageal eosinophils and improvement in clinical symptoms 4
- Fluticasone is particularly effective in the proximal esophagus and in younger, non-allergic individuals 2
- Compounded fluticasone suspensions have shown efficacy even in treatment-refractory EOE populations 3
Practical Administration with Honey
- Empty fluticasone MDI puffs into a small amount of honey (approximately 1-2 teaspoons) 1, 3
- Swallow the mixture without chewing to maximize esophageal contact time 1
- Avoid eating, drinking, or rinsing for 30 minutes after administration 1
- Administer twice daily for optimal effect 1, 4
Efficacy and Safety Considerations
Efficacy
- Histologic response (defined as <15 eosinophils/high-power field) occurs in 64-71% of patients 5
- Clinical symptoms typically improve within 4-8 weeks of treatment 4, 6
- Endoscopic features (furrows, rings, exudates) also improve with treatment 4, 6
Safety Considerations
- Local side effects include esophageal candidiasis (12-16% of patients) 5
- Oral thrush occurs in 2-3% of patients 5
- Systemic side effects are minimal at recommended doses 7
- Growth is not impeded with long-term use in children 4
Treatment Monitoring
- Repeat endoscopy with biopsies is recommended to assess histologic response 1
- If symptoms recur while on treatment, repeat endoscopy is indicated 1
- Clinical and histological relapse is high after withdrawal of topical steroid treatment, so maintenance therapy is often needed 1
Important Caveats
- Fluticasone is not FDA-approved specifically for EOE treatment in the United States (off-label use) 1
- Patients with significant strictures may require endoscopic dilation in addition to anti-inflammatory therapy 1
- Patients with refractory disease or significant concomitant atopic disease should be jointly managed by gastroenterology and allergy specialists 1
- Medical treatment with topical steroids may reduce the development of strictures in EOE 1